本報告已在2011年07月19日停止出版。
在各產業領域裡，專門從事成長市場的戰略性調查的市調公司Business Communications Company, Inc.（總公司：康乃迪克州），認為限制的改變與"Single isomer"（單一同質異構物）醫藥需求的 提高，無不造成研發成本的增加，而競爭勢力的抬頭、"Single isomer"新藥的開發、市場的全球化、顧客底層的變化等因素，也影響所有與對掌異構物技術 有關的市場。因此，該公司針對技術開發與其傾向進行調查分析，將未來的預測加以統整並出版 "Opportunities in Chiral Technology"調查報告書。
此報告書主要針對 對掌異構物的合成、分離及分析技術進行詳細分析，並在下面的內容裡對於各市場的動向及預測、政府機關的規範、主要專利等進行探討。 1.前言2.摘要3.概要4.掌異構物分子技術: 分離與合成5.管制6.企業結構7.掌異構物合成技術市場
- 市場型態
- 掌異構物中間體
- 掌異構物催化劑
- 掌異構物活體催化劑（酵素）
- 掌異構物助劑
- 其他（掌異構物合成材料）
8.掌異構物分離技術市場
9.掌異構物分析技術市場
10.技術
- 開發
- 主要專利（技術別、應用別、企業別、國別、申請者別）
11.不同用途所見的市場
- 總銷售預測
- 應用（製藥、掌異構物舊藥及新藥、鎮痛劑、麻醉藥、抗感染藥、循環系統藥品、中樞神經系統）
12.全球概觀13.企業資料（50家）
INTRODUCTION
STUDY OBJECTIVES
This report updates a BCC report on the same topic, which was published in
June 2000, and has been updated to include the newer products in the market that
use chiral technology, with more emphasis on racemic switching, which is
currently in demand within the industry. Business Communication Company's
(BCC's) goal in conducting this study was to provide an overview to the chiral
market, which seems to be rising at a very fast pace, and to study the present
and future trends of the chiral technologies. The study was also conducted to
examine the market size and leaders, as well as the synthesis, separation, and
analysis of the chiral products. The report deals with topics like what is
chiral technology, what are the current and potential applications of chiral
technology, what is the U.S./worldwide market value of chiral
technology-enabling products, and what is the market value of products emerging
from chiral technology applications. The basic principles underlying the
synthesis, separation, and analysis of chiral products is also discussed, as
well as their usage over a 5-year period from 2003 to 2008. The companies
selling these products were brought to the forefront, and the factors affecting
markets for these products and how those markets are likely to change, are
discussed. Our key objective was to present a comprehensive analysis of the
current market and its future direction in chiral technology, with the emphasis
on use of intermediates and chiral products as pharmaceutical drugs.
REASONS FOR DOING THIS STUDY
The chiral technology market is changing due to regulatory changes and the
demand for single isomers. The key industry objective is now 'racemic
switching.' R&D spending, along with increasing competition, single-isomer
drugs, the international marketplace, and a changing customer base are
contributing to creating a new kind of market for chiral technology. This study
examines almost all of the types of chiral technology markets that will be
affected by these factors. Chiral technology focuses mainly on pharmaceutical
drugs. When drug companies discuss their involvement in many different drug
research and commercialization topics (e.g., rational drug design,
receptor-based drugs, enzyme inhibitors, advanced compound screening, and
small-molecule research), they are generally talking about chiral drugs. The
cardiovascular and anti-infective sectors have a large chiral market. More drugs
are being discovered-antivirals that are chiral in nature. Respiratory and
oncology chiral drugs can also expect a good future in next few years. The
growth by acquisition strategies and the collaborations by companies to gain
better market share is also covered in this report. This study discusses the
strength and weaknesses of the chiral technology market in light of the new
technologies, growing competition, and changing customer needs. The market is
looking into the single enantiomeric forms. To cite an example, consider the
tragedy of thalidomide in 1960s. The drug was prescribed to pregnant women to
counter morning sickness. Tragically, while the (S)-isomer had the desired
antinausea effects, the (R)-form was teratogenic and caused fetal abnormalities,
such as severely underdeveloped limbs. Unfortunately, in the case of
thalidomide, however, giving the pure (S)-enantiomer would not have solved the
problem. The pure isomers of thalidomide racemise within 10 minutes in the
bloodstream, so even the enantiomerically pure drug would not have prevented the
terrible side effects. But there are certain racemates whose enantiomers have
different effects, unless those enantiomers racemise in the body. Scientists are
studying and developing those drugs with single enantiomers that have more
activity than their racemates.
CONTRIBUTIONS TO THE STUDY
This study examines the areas of growth and decline within the chiral
industry, as well as looking at chiral technology from the point of view of
manufacturers as well as the users. We present the various types of synthesis,
separation, and analysis techniques of chiral technology. The regulations
governing their use, technological descriptions and issues, applications, market
factors and potential, and the projected market for 2003 - 2008 are also
studied. This report will be of interest largely to the pharmaceutical industry,
as well as biochemical, pesticide, and research companies interested in new
chiral drugs or compounds. It also contributes by bringing together in one
place much of the information on new products and new technologies in chiral
technology, and serves as a source for estimates about the consumption of
various chiral products.
SCOPE OF THE STUDY
The scope of this study encompasses the synthesis, separation, and analysis
of chiral technology. BCC analyzes each technique, and presents insight on
manufacturers, new products, sales estimates, market projections, and market
share information. Technological issues include the latest trends and
development. We have examined the regulations set by government agencies, such
as the Food and Drug Administration (FDA), and have also covered recent
approvals of chiral drug products. Patents in chiral technology have been dealt
with at large, given their significance.
METHODOLOGY
A comprehensive literature and patent search was conducted. Literature
included technical newsletters and journals, as well as many other sources. The
data was collected through interviews/mails of various analytical, chemical,
pharmaceutical, and biotech companies. This data was complied, and projections
were based on such estimates as the current number of end users, potential end
users, likely unit prices, rates of consumption, and the market trends.
INFORMATION SOURCES
BCC surveyed many companies in order to obtain the data for this study.
Included were manufacturers and the end users of the chiral technology. In
addition to gathering the data from these industries, we also spoke with
industry officials, and consulted newsletters, company literature, and product
literature, as well as a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were done.
In addition, we compiled data from current financial and trade information, and
government sources. TABLE OF CONTENTS
INTRODUCTION
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS TO THE STUDY
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC REPORTS
- BCC ONLINE SERVICES
SUMMARY
Summary Table:
SALES OF CHIRAL TECHNOLOGY PRODUCTS BY CATEGORY IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Summary Figure:
SALES OF CHIRAL TECHNOLOGY PRODUCTS BY CATEGORY IN THE U.S., 2001-2008 ($
MILLIONS)
OVERVIEW
- WHAT IS CHIRALITY?
- Chain or Nuclear Isomerism
- Functional Group Isomerism
- DESIGNATION OF OPTICAL ISOMERS
- THE NATURE OF CHIRAL ISOMERISM
- IMPORTANCE OF CHIRALITY IN PHARMACEUTICALS
TWO ASPECTS OF CHIRAL TECHNOLOGY: SEPARATION AND SYNTHESIS
- TWO ASPECTS OF CHIRAL TECHNOLOGY: (CONTINUED)
- SYNTHESIS
- PARTIAL ASYMMETRIC SYNTHESIS
- ABSOLUTE ASYMMETRIC SYNTHESIS
- Functional Group Strategies
- Transform-Based Strategies
- Structure-Goal Strategies
- Stereochemical Strategies
- TYPES OF REACTIONS INVOLVED IN CHIRAL SYNTHESIS
- Enzyme Catalysts in Conserved Chirality
- Table 1 MATERIALS USED FOR CHIRAL SYNTHETIC REACTIONS
- PRODUCTS FOR CHIRAL SYNTHESIS
- Chiral Epoxides and Glycidols
- Substituted Chiral Propionic Acids
- Table 2 NOTABLE CHIRAL INTERMEDIATES
- Asymmetric Chemical Catalysts
- Table 3 NOTABLE CHIRAL CATALYSTS
- Chiral Hydrogenation Catalysts
- Sharpless and Jacobsen Epoxidation Catalysts
- Sharpless and Jacobsen Epoxidation Catalysts (Continued)
- Sharpless Dihydroxylation Catalyst
- Regis Technologies' Doyle Catalysts
- Asymmetric Hydroformylation
- Aldol Condensation Catalysts
- Table 4 CHIRAL CHEMICAL CATALYSTS VS. ENZYME CATALYSTS
- Chiral Biocatalysts (Enzymes)
- Chiral Biocatalysts (Enzymes) (Continued)
- Some Chiral Auxiliary Compounds
- Other Chiral Synthesis Materials
- Chiral Acid and Base Catalysts
- SEPARATION
- PHYSICAL SEPARATION TECHNOLOGIES
- Chiral Crystallization Principles
- Preferential Crystallization
- Diastereomeric Crystallization
- Diastereomeric Crystallization (Continued)
- Precipitating (Resolving) Agents
- Table 5 RESOLVING AGENTS FOR DIASTEREOMER CRYSTALLIZATION
- Table 5 (CONTINUED)
- The Principle of Chiral Chromatography
- Types of Preparative Chiral Chromatography
- Preparative Chiral Chromatography Stationary Phases
- ENZYME-BASED KINETIC SEPARATION TECHNOLOGY
- Enzyme-Based Kinetic Separation Technology (Continued)
- Table 6 MAJOR APPLICATIONS OF ENZYMATIC KINETIC RESOLUTION
- OTHER SEPARATIVE TECHNIQUES
- Receptor-Based Resolution
REGULATORY ASPECTS
- REGULATIONS GOVERNING CHIRAL TECHNOLOGY
- Developing a Single Stereoisomer after the Racemate is Studied
- Developing A Single Stereoisomer After The Racemate Is Studied
(Continued)
- NON-FEDERAL RULES AND REGULATIONS
- NEW APPROVALS
- Table 7 NEW AND GENERIC APPROVALS OF CHIRAL DRUGS EXISTING AS ISOMERS,
2001-2003
- Table 7 (CONTINUED)
- Table 7 (CONTINUED)
- Table 7 (CONTINUED)
- Table 7 (CONTINUED)
- Table 7 (CONTINUED)
INDUSTRY STRUCTURE
- Table 8 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
INTERMEDIATES, 2002 (%)
- Figure 1 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
INTERMEDIATES, 2002 (%)
- CHIRAL CHEMICAL CATALYSTS
- Table 9 SUPPLIERS AND MANUFACTURERS OF CHIRAL CHEMICAL CATALYSTS
- CHIRAL BIOCATALYSTS (ENZYMES)
- Table 10 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
BIOCATALYSTS, 2002 (%)
- Figure 2 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
BIOCATALYSTS, 2002 (%)
- CHIRAL CHROMATOGRAPHY REAGENTS
- Table 11 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
CHROMATOGRAPHY REAGENTS, 2002 (%)
- Figure 3 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
CHROMATOGRAPHY REAGENTS, 2002 (%)
- CHIRAL KINETIC RESOLUTION
- Table 12 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
KINETIC RESOLUTION ENZYMES, 2002
- Figure 4 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
KINETIC RESOLUTION ENZYMES, 2000 (%)
- Table 13 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
ANALYSIS INSTRUMENTS, 2002
- Figure 5 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
ANALYSIS INSTRUMENTS, 2002 (%)
- TYPES OF INDUSTRIES
- DEMAND AND USE OF CHIRAL DRUGS
- THE CHANGING CHIRAL INDUSTRY
THE CHIRAL SYNTHESIS MARKET
- Table 14 SALES OF CHIRAL SYNTHETIC MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Figure 6 SALES OF CHIRAL SYNTHETIC MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 7 ESTIMATED MARKET SHARE OF CHIRAL SYNTHESIS MATERIALS, 2002 (%)
- MARKET BY TYPE
- Chiral Intermediates Industry Leaders
- Table 15 SALES OF CHIRAL INTERMEDIATES IN THE U.S., THROUGH 2008 ($
MILLIONS)
- CHIRAL CHEMICAL CATALYSTS
- Table 16 SALES OF CHIRAL CHEMICAL CATALYSTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- CHIRAL BIOCATALYSTS (ENZYMES)
- Chiral Biocatalysts (Enzymes) (Continued)
- Table 17 SALES OF CHIRAL BIOCATALYSTS IN THE U.S., THROUGH 2008 ($
THOUSANDS)
- Table 18 SALES OF CHIRAL AUXILIARIES IN THE U.S., THROUGH 2008 ($
MILLIONS)
- OTHER CHIRAL SYNTHESIS MATERIALS
- Table 19 SALES OF OTHER CHIRAL SYNTHESIS MATERIALS IN THE U.S., THROUGH
2008 ($ MILLIONS)
THE CHIRAL SEPARATION MARKET
- Table 20 SALES OF CHIRAL SEPARATION MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Figure 8 SALES OF CHIRAL SEPARATION MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 9 ESTIMATED MARKET SHARES OF CHIRAL SEPARATION PRODUCTS, 2002 (%)
- Table 21 SALES OF CHIRAL CRYSTALLIZING AGENTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 22 SALES OF CHIRAL CHROMATOGRAPHY REAGENTS AND COLUMNS IN THE U.S.,
THROUGH 2008 ($ MILLIONS)
- Table 23 SALES OF CHIRAL SOLVENT EXTRACTION REAGENTS AND INSTRUMENTS IN
THE U.S., THROUGH 2008 ($ MILLIONS)
- Table 24 SALES IN CHIRAL KINETIC RESOLUTION IN THE U.S., THROUGH 2008 ($
MILLIONS)
CHIRAL ANALYSIS MARKET
- Table 25 SALES OF CHIRAL ANALYSIS MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Figure 10 SALES OF CHIRAL ANALYSIS MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 11 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF
CHIRAL ANALYSIS, 2002 (%)
- MARKET BY TYPE
- MARKET BY TYPE (CONTINUED)
- CHIRAL ANALYTICAL CHROMATOGRAPHY
- Chiral Liquid Chromatography
- Chiral Liquid Chromatography (Continued)
- Chiral Gas Chromatography
- Table 26 AGENTS USED TO FORM CHIRAL DERIVATIVES FOR GC ANALYSIS
- Table 27 ADVANTAGES OF CHIRAL LIQUID CHROMATOGRAPHY VS. CHIRAL GAS
CHROMATOGRAPHY
- Capillary Electrophoresis
- Chiral Supercritical Fluid Chromatography
- Chiral Supercritical Fluid Chromatography (Continued)
- Table 28 SALES IN CHIRAL ANALYTICAL CHROMATOGRAPHY IN THE U.S., THROUGH
2008 ($ MILLIONS)
- Table 29 SALES OF REAGENTS IN CHIRAL POLARIMETRY IN THE U.S., THROUGH 2008
($ MILLIONS)
- NUCLEAR MAGNETIC RESONANCE
- Table 30 SALES IN CHIRAL NMR-SHIFT REAGENTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- OTHER CHIRAL ANALYTICAL TECHNIQUES
- X-Ray Crystallography (Continued)
TECHNOLOGY
- DEVELOPMENTS
- SIGNIFICANT PATENTS
- Table 31 PATENTS BY TECHNOLOGY, 1998-2003
- Table 31 (CONTINUED)
- Figure 12 NUMBER OF PATENTS BY TECHNOLOGY, PER YEAR, 1998-2003
- Figure 13 TOTAL NUMBER OF PATENTS, SYNTHESIS VS. SEPARATION, 1998-2003 (%)
- Table 32 SIGNIFICANT PATENTS, SYNTHESIS IN CHIRAL TECHNOLOGY, 1998-2003
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 32 (CONTINUED)
- Table 33 SIGNIFICANT PATENTS IN CHIRAL TECHNOLOGY, BY SEPARATION
TECHNIQUE, 1998-2003
- Table 33 (CONTINUED)
- Table 33 (CONTINUED)
- Table 33 (CONTINUED)
- Table 34 SIGNIFICANT PATENTS IN CHIRAL TECHNOLOGY, BY DISEASE SECTOR,
1998-2003
- Table 34 (CONTINUED)
- Table 35 PATENTS BY ABBOTT LABORATORIES IN CHIRAL TECHNOLOGY, 1998-2003
- Table 36 PATENTS BY BECKMAN COULTER IN CHIRAL TECHNOLOGY, 1998-2003
- Table 37 PATENTS BY BEND RESEARCH IN CHIRAL TECHNOLOGY, 1998-2003
- Table 38 PATENTS BY BIOCATALYTICS, INC. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 39 PATENTS BY BRISTOL-MEYERS SQUIBB, INC. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 40 PATENTS BY BOULDER SCIENTIFIC IN CHIRAL TECHNOLOGY, 1998-2003
- Table 41 PATENTS BY CELEGEN IN CHIRAL TECHNOLOGY, 1998-2003
- Table 42 PATENTS BY CHIROTECH TECHNOLOGY IN CHIRAL TECHNOLOGY, 1998-2003
- Table 43 PATENTS BY DAICEL CHEMICAL INDUSTRIES IN CHIRAL TECHNOLOGY,
1998-2003
- Table 44 PATENTS BY DSM FINE CHEMICALS IN CHIRAL TECHNOLOGY, 1998-2003
- Table 45 PATENTS BY EASTMAN CHEMICAL CO. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 46 PATENTS BY GENZYME IN CHIRAL TECHNOLOGY, 1998-2003
- Table 47 PATENTS BY GREAT LAKES CHEMICAL CORP. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 48 PATENTS BY LONZA GROUP IN CHIRAL TECHNOLOGY, 1998-2003
- Table 49 PATENTS BY MACHEREY-NAGEL & CO. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 50 PATENTS BY MERCK & CO. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 51 PATENTS BY NOVASEP IN CHIRAL TECHNOLOGY, 1998-2003
- Table 52 PATENTS BY PFIZER IN CHIRAL TECHNOLOGY, 1998-2003
- Table 53 PATENTS BY PHARM-ECO IN CHIRAL TECHNOLOGY, 1998-2003
- Table 54 PATENTS BY RHODIA IN CHIRAL TECHNOLOGY, 1998-2003
- Table 55 U.S. PATENTS BY COUNTRY, 1998-2003
- Figure 14 U.S. PATENTS BY COUNTRY, 1998-2003
- Table 56 NUMBER AND SHARE OF U.S. PATENTS BY ASSIGNEE, 1998-2003
- Figure 15 NUMBER OF U.S. PATENTS BY ASSIGNEE, 1998-2003
- Figure 16 SHARES OF U.S PATENTS BY ASSIGNEE, 1998-2003 (%)
MARKET BY APPLICATIONS
- Table 57 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY MAJOR
APPLICATION, THROUGH 2008 ($ MILLIONS)
- Figure 17 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY MAJOR
APPLICATIONS, 2001-2008 ($ MILLIONS)
- Table 58 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PRODUCT TYPE,
THROUGH 2008 ($ MILLIONS)
- Table 59 PERCENT (%) OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PRODUCT
TYPE, 2002
- Table 60 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PHARMACEUTICAL
APPLICATION, THROUGH 2008 ($ MILLIONS)
- Table 61 U.S. SALES OF PHARMACEUTICALS, 1998-2002 ($ MILLIONS)
- Table 62 U.S. EXPENDITURES IN R&D IN THE PHARMACEUTICAL INDUSTRY,
1998-2002 ($ MILLIONS)
- Table 63 U.S. SALES OF SYNTHETIC CHIRAL DRUGS BY MAJOR APPLICATIONS,
THROUGH 2008 ($ BILLIONS)
- RETROSPECTIVE AND PROSPECTIVE CHIRAL DRUG ACTIVITIES
- Retrospective Applications
- Ibuprofen and Other Profens
- Table 64 CHIRAL ANALGESICS
- Table 65 CHIRAL ANESTHETICS
- Table 65 (CONTINUED)
- Semisynthetic Antibiotics with Chiral Components
- Table 66 CHIRAL ADDUCTS USED TO PRODUCE SEMISYNTHETIC ANTIBIOTICS
- Synthetic Chiral Anti-infectives
- Table 67 SYNTHETIC CHIRAL ANTI-INFECTIVE DRUGS
- CARDIOVASCULAR SYSTEM PRODUCTS
- Table 68 CHIRAL ACE INHIBITORS
- Angiotensin II Receptor Antagonists
- Table 69 CHIRAL BETA-BLOCKERS
- Table 69 (CONTINUED)
- Calcium Channel Blockers (Continued)
- Table 70 CHIRAL CALCIUM CHANNEL BLOCKERS
- Cholesterol-Lowering Agents
- Table 71 CHIRAL HMG-CoA REDUCTASE INHIBITORS
- Dedicated Antiarrhythmic Drugs
- Table 72 CHIRAL DEDICATED ANTIARRHYTHMIA DRUGS
- Table 73 CHIRAL DIURETICS
- Table 74 CHIRAL VASODILATORS
- Other Antihypertensive Drugs
- CENTRAL NERVOUS SYSTEM AGENTS
- Table 75 CHIRAL ANTICONVULSANT DRUGS
- Parkinson's Disease Agents
- Table 76 CHIRAL PARKINSON'S DISEASE AGENTS
- Sedatives and Tranquilizers
- Table 77 CHIRAL SEDATIVES AND TRANQUILIZERS
- Stimulants and Antidepressants
- Table 78 CHIRAL STIMULANTS AND ANTIDEPRESSANTS
- ENDOCRINE SYSTEM DISORDER PRODUCTS
- Table 79 CHIRAL ANTIDIABETES DRUGS
- GASTROINTESTINAL PRODUCTS
- Table 80 CHIRAL GASTROINTESTINAL DRUGS
- Table 81 CHIRAL HEMATOLOGY DRUGS
- ONCOGENIC (CANCER-TREATMENT) PRODUCTS
- Table 82 CHIRAL ONCOGENIC DRUGS
- Other New Anticancer Agents
- RESPIRATORY SYSTEM PRODUCTS
- Table 83 POPULAR CHIRAL COUGH AND COLD REMEDIES
- Products for More Serious Respiratory Problems
- Table 84 CHIRAL DRUGS FOR ASTHMA AND OTHER CHRONIC RESPIRATORY DISEASES
- Table 85 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS FOR BIOMEDICAL
APPLICATIONS, THROUGH 2008 ($ MILLIONS)
- Table 86 COMMERCIAL METHODS FOR MANUFACTURING NATURAL AMINO ACIDS
- Amino Acids in Chiral Drug Development
- SUGARS AND OTHER OLIGOSACCHARIDES
- Table 87 CHIRAL VITAMINS AND THEIR MANUFACTURING METHODS
- Table 87 (CONTINUED)
- Table 88 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS FOR PESTICIDE
APPLICATIONS, THROUGH 2008 ($ MILLIONS)
- CHIRAL PESTICIDE OVERVIEW
- Table 89 U.S. PESTICIDE CONSUMPTION, 1999 (MILLION POUNDS)
- Chiral Pesticide Overview (Continued)
- Table 90 CHEMICAL PESTICIDE CHIRALITY
- Table 90 (CONTINUED)
- Table 90 (CONTINUED)
- Table 91 NUMBER OF CHIRAL VS. NON-CHIRAL PESTICIDE PRODUCTS
- Figure 18 SHARE OF CHIRAL PRODUCTS IN PESTICIDES (%)
- Table 92 SALES OF OTHER CHIRAL TECHNOLOGY-ENABLING PRODUCTS, THROUGH 2008
($ MILLIONS)
- AROMA AND FLAVOR CHEMICALS
- Chiral Aroma/Flavor Compounds
- Table 93 NOTABLE CHIRAL AROMA AND FLAVOR COMPOUNDS
- NONLINEAR OPTICAL MATERIALS
INTERNATIONAL ASPECTS
- Table 94 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, THROUGH 2008 ($ MILLIONS)
- Figure 19 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, 2001-2008 ($ MILLIONS)
- Figure 20 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, 2002 (% OF TOTAL)
- Figure 20 (CONTINUED)
- Table 95 WORLDWIDE SALES OF SYNTHETIC CHIRAL DRUGS, THROUGH 2008 ($
BILLIONS)
- Figure 21 WORLDWIDE SALES OF SYNTHETIC CHIRAL DRUGS, 2001-2008 ($
BILLIONS)
COMPANY PROFILES
- ABBOTT LABORATORIES
- ALTUS BIOLOGICS, INC.
- AVECIA, INC.
- BASF CORP.
- BECKMAN COULTER
- BEND RESEARCH, INC.
- BIOCATALYTICS, INC.
- BOULDER SCIENTIFIC
- CAMBREX CORP.
- CAMBREX CORP. (CONTINUED)
- CELGENE CORP.
- DIVERSA CORP.
- DIVERSA CORP. (CONTINUED)
- DIGITAL SPECIALTY CHEMICALS
- DSM FINE CHEMICALS
- DAICEL CHEMICAL INDUSTRIES
- DAVOS CHEMICAL CORP.
- DOWPHARMA
- EASTMAN CHEMICAL CO.
- FISHER SCIENTIFIC, INTL.
- GENENCOR INTERNATIONAL, INC.
- GENZYME CORP.
- GREAT LAKES CHEMICAL CO.
- JASCO, INC.
- JOHNSON MATTHEY PLC
- JOHNSON MATTHEY CATALYSTS
- J.T.BAKER, INC.
- LONZA GROUP, LTD.
- MACHEREY-NAGEL, INC.
- MAXYGEN
- MERCK KGAA
- EMD LEXIGEN RESEARCH CENTER CORP.
- EMD PHARMACEUTICALS, INC.
- NOVASEP, INC.
- PHARM-ECO
- PFIZER
- PDR-CHIRAL, INC.
- PERKIN ELMER, INC.
- PHENOMENEX, INC.
- PPG-SIPSY
- RHODIA, INC.
- ROCHE DIAGNOSTICS CORP.
- RUDOLPH INSTRUMENTS
- REGIS TECHNOLOGIES, INC.
- SEDERE, INC.
- SIGMA-ALDRICH
- SEPRACOR, INC.
- SK ENERGY & CHEMICAL
- STREM CHEMICALS, INC.
- SYNTHETECH, INC.
- SYNTHON CHIRAGENICS CORP.
- THERMOGEN, INC.
- UNIVERSAL PHARMA TECHNOLOGIES, LLC
LIST OF TABLES
- Summary Table:
SALES OF CHIRAL TECHNOLOGY PRODUCTS BY CATEGORY IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 1 MATERIALS USED FOR CHIRAL SYNTHETIC REACTIONS
- Table 2 NOTABLE CHIRAL INTERMEDIATES
- Table 3 NOTABLE CHIRAL CATALYSTS
- Table 4 CHIRAL CHEMICAL CATALYSTS VS. ENZYME CATALYSTS
- Table 5 RESOLVING AGENTS FOR DIASTEREOMER CRYSTALLIZATION
- Table 6 MAJOR APPLICATIONS OF ENZYMATIC KINETIC RESOLUTION
- Table 7 NEW AND GENERIC APPROVALS OF CHIRAL DRUGS EXISTING AS ISOMERS,
2001-2003
- Table 8 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
INTERMEDIATES, 2002 (%)
- Table 9 SUPPLIERS AND MANUFACTURERS OF CHIRAL CHEMICAL CATALYSTS
- Table 10 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
BIOCATALYSTS, 2002 (%)
- Table 11 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
CHROMATOGRAPHY REAGENTS, 2002 (%)
- Table 12 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
KINETIC RESOLUTION ENZYMES, 2002
- Table 13 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
ANALYSIS INSTRUMENTS, 2002
- Table 14 SALES OF CHIRAL SYNTHETIC MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 15 SALES OF CHIRAL INTERMEDIATES IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 16 SALES OF CHIRAL CHEMICAL CATALYSTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 17 SALES OF CHIRAL BIOCATALYSTS IN THE U.S., THROUGH 2008 ($
THOUSANDS)
- Table 18 SALES OF CHIRAL AUXILIARIES IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 19 SALES OF OTHER CHIRAL SYNTHESIS MATERIALS IN THE U.S., THROUGH
2008 ($ MILLIONS)
- Table 20 SALES OF CHIRAL SEPARATION MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 21 SALES OF CHIRAL CRYSTALLIZING AGENTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 22 SALES OF CHIRAL CHROMATOGRAPHY REAGENTS AND COLUMNS IN THE U.S.,
THROUGH 2008 ($ MILLIONS)
- Table 23 SALES OF CHIRAL SOLVENT EXTRACTION REAGENTS AND INSTRUMENTS IN
THE U.S., THROUGH 2008 ($ MILLIONS)
- Table 24 SALES IN CHIRAL KINETIC RESOLUTION IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 25 SALES OF CHIRAL ANALYSIS MATERIALS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 26 AGENTS USED TO FORM CHIRAL DERIVATIVES FOR GC ANALYSIS
- Table 27 ADVANTAGES OF CHIRAL LIQUID CHROMATOGRAPHY VS. CHIRAL GAS
CHROMATOGRAPHY
- Table 28 SALES IN CHIRAL ANALYTICAL CHROMATOGRAPHY IN THE U.S., THROUGH
2008 ($ MILLIONS)
- Table 29 SALES OF REAGENTS IN CHIRAL POLARIMETRY IN THE U.S., THROUGH 2008
($ MILLIONS)
- Table 30 SALES IN CHIRAL NMR-SHIFT REAGENTS IN THE U.S., THROUGH 2008 ($
MILLIONS)
- Table 31 PATENTS BY TECHNOLOGY, 1998-2003
- Table 32 SIGNIFICANT PATENTS, SYNTHESIS IN CHIRAL TECHNOLOGY, 1998-2003
- Table 33 SIGNIFICANT PATENTS IN CHIRAL TECHNOLOGY, BY SEPARATION
TECHNIQUE, 1998-2003
- Table 34 SIGNIFICANT PATENTS IN CHIRAL TECHNOLOGY, BY DISEASE SECTOR,
1998-2003
- Table 35 PATENTS BY ABBOTT LABORATORIES IN CHIRAL TECHNOLOGY, 1998-2003
- Table 36 PATENTS BY BECKMAN COULTER IN CHIRAL TECHNOLOGY, 1998-2003
- Table 37 PATENTS BY BEND RESEARCH IN CHIRAL TECHNOLOGY, 1998-2003
- Table 38 PATENTS BY BIOCATALYTICS, INC. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 39 PATENTS BY BRISTOL-MEYERS SQUIBB, INC. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 40 PATENTS BY BOULDER SCIENTIFIC IN CHIRAL TECHNOLOGY, 1998-2003
- Table 41 PATENTS BY CELEGEN IN CHIRAL TECHNOLOGY, 1998-2003
- Table 42 PATENTS BY CHIROTECH TECHNOLOGY IN CHIRAL TECHNOLOGY, 1998-2003
- Table 43 PATENTS BY DAICEL CHEMICAL INDUSTRIES IN CHIRAL TECHNOLOGY,
1998-2003
- Table 44 PATENTS BY DSM FINE CHEMICALS IN CHIRAL TECHNOLOGY, 1998-2003
- Table 45 PATENTS BY EASTMAN CHEMICAL CO. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 46 PATENTS BY GENZYME IN CHIRAL TECHNOLOGY, 1998-2003
- Table 47 PATENTS BY GREAT LAKES CHEMICAL CORP. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 48 PATENTS BY LONZA GROUP IN CHIRAL TECHNOLOGY, 1998-2003
- Table 49 PATENTS BY MACHEREY-NAGEL & CO. IN CHIRAL TECHNOLOGY,
1998-2003
- Table 50 PATENTS BY MERCK & CO. IN CHIRAL TECHNOLOGY, 1998-2003
- Table 51 PATENTS BY NOVASEP IN CHIRAL TECHNOLOGY, 1998-2003
- Table 52 PATENTS BY PFIZER IN CHIRAL TECHNOLOGY, 1998-2003
- Table 53 PATENTS BY PHARM-ECO IN CHIRAL TECHNOLOGY, 1998-2003
- Table 54 PATENTS BY RHODIA IN CHIRAL TECHNOLOGY, 1998-2003
- Table 55 U.S. PATENTS BY COUNTRY, 1998-2003
- Table 56 NUMBER AND SHARE OF U.S. PATENTS BY ASSIGNEE, 1998-2003
- Table 57 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY MAJOR
APPLICATION, THROUGH 2008 ($ MILLIONS)
- Table 58 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PRODUCT TYPE,
THROUGH 2008 ($ MILLIONS)
- Table 59 PERCENT (%) OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PRODUCT
TYPE, 2002
- Table 60 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY PHARMACEUTICAL
APPLICATION, THROUGH 2008 ($ MILLIONS)
- Table 61 U.S. SALES OF PHARMACEUTICALS, 1998-2002 ($ MILLIONS)
- Table 62 U.S. EXPENDITURES IN R&D IN THE PHARMACEUTICAL INDUSTRY,
1998-2002 ($ MILLIONS)
- Table 63 U.S. SALES OF SYNTHETIC CHIRAL DRUGS BY MAJOR APPLICATIONS,
THROUGH 2008 ($ BILLIONS)
- Table 64 CHIRAL ANALGESICS
- Table 65 CHIRAL ANESTHETICS
- Table 66 CHIRAL ADDUCTS USED TO PRODUCE SEMISYNTHETIC ANTIBIOTICS
- Table 67 SYNTHETIC CHIRAL ANTI-INFECTIVE DRUGS
- Table 68 CHIRAL ACE INHIBITORS
- Table 69 CHIRAL BETA-BLOCKERS
- Table 70 CHIRAL CALCIUM CHANNEL BLOCKERS
- Table 71 CHIRAL HMG-CoA REDUCTASE INHIBITORS
- Table 72 CHIRAL DEDICATED ANTIARRHYTHMIA DRUGS
- Table 73 CHIRAL DIURETICS
- Table 74 CHIRAL VASODILATORS
- Table 75 CHIRAL ANTICONVULSANT DRUGS
- Table 76 CHIRAL PARKINSON'S DISEASE AGENTS
- Table 77 CHIRAL SEDATIVES AND TRANQUILIZERS
- Table 78 CHIRAL STIMULANTS AND ANTIDEPRESSANTS
- Table 79 CHIRAL ANTIDIABETES DRUGS
- Table 80 CHIRAL GASTROINTESTINAL DRUGS
- Table 81 CHIRAL HEMATOLOGY DRUGS
- Table 82 CHIRAL ONCOGENIC DRUGS
- Table 83 POPULAR CHIRAL COUGH AND COLD REMEDIES
- Table 84 CHIRAL DRUGS FOR ASTHMA AND OTHER CHRONIC RESPIRATORY DISEASES
- Table 85 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS FOR BIOMEDICAL
APPLICATIONS, THROUGH 2008 ($ MILLIONS)
- Table 86 COMMERCIAL METHODS FOR MANUFACTURING NATURAL AMINO ACIDS
- Table 87 CHIRAL VITAMINS AND THEIR MANUFACTURING METHODS
- Table 88 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS FOR PESTICIDE
APPLICATIONS, THROUGH 2008 ($ MILLIONS)
- Table 89 U.S. PESTICIDE CONSUMPTION, 1999 (MILLION POUNDS)
- Table 90 CHEMICAL PESTICIDE CHIRALITY
- Table 91 NUMBER OF CHIRAL VS. NON-CHIRAL PESTICIDE PRODUCTS
- Table 92 SALES OF OTHER CHIRAL TECHNOLOGY-ENABLING PRODUCTS, THROUGH 2008
($ MILLIONS)
- Table 93 NOTABLE CHIRAL AROMA AND FLAVOR COMPOUNDS
- Table 94 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, THROUGH 2008 ($ MILLIONS)
- Table 95 WORLDWIDE SALES OF SYNTHETIC CHIRAL DRUGS, THROUGH 2008 ($
BILLIONS)
LIST OF FIGURES
- Summary Figure:
SALES OF CHIRAL TECHNOLOGY PRODUCTS BY CATEGORY IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 1 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
INTERMEDIATES, 2002 (%)
- Figure 2 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
BIOCATALYSTS, 2002 (%)
- Figure 3 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
CHROMATOGRAPHY REAGENTS, 2002 (%)
- Figure 4 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
KINETIC RESOLUTION ENZYMES, 2000 (%)
- Figure 5 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF CHIRAL
ANALYSIS INSTRUMENTS, 2002 (%)
- Figure 6 SALES OF CHIRAL SYNTHETIC MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 7 ESTIMATED MARKET SHARE OF CHIRAL SYNTHESIS MATERIALS, 2002 (%)
- Figure 8 SALES OF CHIRAL SEPARATION MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 9 ESTIMATED MARKET SHARES OF CHIRAL SEPARATION PRODUCTS, 2002 (%)
- Figure 10 SALES OF CHIRAL ANALYSIS MATERIALS IN THE U.S., 2001-2008 ($
MILLIONS)
- Figure 11 ESTIMATED MARKET SHARES FOR SUPPLIERS AND MANUFACTURERS OF
CHIRAL ANALYSIS, 2002 (%)
- Figure 12 NUMBER OF PATENTS BY TECHNOLOGY, PER YEAR, 1998-2003
- Figure 13 TOTAL NUMBER OF PATENTS, SYNTHESIS VS. SEPARATION, 1998-2003 (%)
- Figure 14 U.S. PATENTS BY COUNTRY, 1998-2003
- Figure 15 NUMBER OF U.S. PATENTS BY ASSIGNEE, 1998-2003
- Figure 16 SHARES OF U.S PATENTS BY ASSIGNEE, 1998-2003 (%)
- Figure 17 SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS BY MAJOR
APPLICATIONS, 2001-2008 ($ MILLIONS)
- Figure 18 SHARE OF CHIRAL PRODUCTS IN PESTICIDES (%)
- Figure 19 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, 2001-2008 ($ MILLIONS)
- Figure 20 WORLDWIDE SALES OF CHIRAL TECHNOLOGY-ENABLING PRODUCTS:
GEOGRAPHIC BREAKDOWN, 2002 (% OF TOTAL)
- Figure 21 WORLDWIDE SALES OF SYNTHETIC CHIRAL DRUGS, 2001-2008 ($
BILLIONS)
|
